Greenhaven Road Capital Main Fund Q1 2025 Top 5 Holdings
Lifecore, Burford, KKR, PAR, and Cellebrite are well-positioned despite trade policy and tariff headwinds, each with unique catalysts for growth. KKR stands out for its asset growth, brand strength, and resilience, benefiting from the migration to private assets and high-net-worth channels. PAR's high-margin software, resilient QSR customer base, and strong growth prospects outweigh tariff risks and support a bullish outlook.
FS KKR Capital: Exceeding A 10% Yield After Outlining Q2 Guidance
FSK delivered a strong Q1 2025, surpassing NII guidance and reaffirming a $0.70 quarterly distribution, highlighting management's proactive risk management and portfolio strength. Shares trade at a -9.41% discount to NAV and just 7.52x NII, offering investors double-digit yields and capital appreciation potential versus peers. FSK's disciplined focus on senior secured debt, robust origination activity, and improved credit metrics position it defensively for future growth.
FS KKR Capital: Weak Q1 Earnings As Dividend Support Weakens
FSK offers a high 13.4% dividend yield, but dividend coverage is barely adequate and NAV continues to decline, raising sustainability concerns. Despite a strong quarter for new investments, persistent non-accruals and weak earnings suggest fundamental issues remain unresolved. FSK trades at a 10.5% discount to NAV, but this is less attractive than its historical average, reflecting market skepticism about quality.
FS KKR Capital: A High-Yielding BDC Underdog
FS KKR Capital's met EPS expectations due to new investments. The BDC grew its portfolio and slightly improved its balance sheet quality, with the non-accrual percentage falling to 2.1%, based on fair value. The Company generated net investment income of $0.67 per share, fully supporting the $0.64 per share regular quarterly dividend.
KKR & Co. Inc. (KKR) Q1 2025 Earnings Call Transcript
KKR & Co. Inc. (NYSE:KKR ) Q1 2025 Earnings Conference Call May 1, 2025 9:00 AM ET Company Participants Craig Larson - Partner and Head of Investor Relations Scott Nuttall - Co-Chief Executive Officer Robert Lewin - Chief Financial Officer Conference Call Participants Craig Siegenthaler - Bank of America Alexander Blostein - Goldman Sachs Benjamin Budish - Barclays Capital Glenn Schorr - Evercore ISI Steve Chubak - Wolfe Research Mike Brown - Wells Fargo Dan Fannon - Jefferies Patrick Davitt - Autonomous Research Arnaud Giblat - BNP Paribas Brian Bedell - Deutsche Bank Michael Cyprys - Morgan Stanley Kyle Voigt - KBW Operator Ladies and gentlemen, thank you for standing by. Welcome to KKR's First Quarter 2025 Earnings Conference Call.
KKR & Co. (KKR) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for KKR & Co. (KKR) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
KKR Gains on Q1 Earnings Beat as Revenues & AUM Rise, Expenses Up Y/Y
Higher revenues and solid growth in AUM balance support KKR & Co.???s Q1 earnings, while a rise in expenses acts as a spoilsport.
Unveiling KKR & Co. (KKR) Q1 Outlook: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of KKR & Co. (KKR) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
KKR Q1 Preview: A Solid Business, But Sentiment Needs To Catch Up
KKR & Co. Inc. is set to report Q1 results on May 1, with low expectations but the potential for a positive surprise, especially after a strong last quarter. The $1.2 billion acquisition of Biotage signals KKR's strategic expansion in life sciences, reinforcing confidence in long-term value despite market challenges. Despite a high valuation and recent stock underperformance, KKR's fundamentals remain strong, with robust cash generation, fundraising momentum, and growing assets under management.
KKR Launches $1.2 Billion Takeover Bid For Swedish Life-Sciences Company Biotage
The deal values the Swedish company at $1.2 billion, and the Biotage board recommended that shareholders accept the offer.
FS KKR Capital: Buy The Tariff Tantrum, Secure A 13.7% Yield
FS KKR Capital's stock is undervalued, trading at a 21% discount to NAV, presenting a compelling buying opportunity despite higher-than-average non-accruals and declining net investment income. The BDC's credit profile has improved compared to 2023, and it could suspend its supplemental dividend to maintain its base dividend. FS KKR Capital's net investment income fell in 4Q24 due to higher loan repayments, leading to a higher dividend pay-out ratio and potential short-term dividend coverage challenges.
FS KKR Capital: How Good Is This 15% Yield?
FS KKR Capital offers a high dividend yield of 15%, with shares trading at an inexpensive valuation, making it an attractive entry point. Despite a 12% decline in net investment income per share, the yield on debt investments remains high, stabilizing with current interest rates. The portfolio has become more diversified, but the non-accrual rate has risen to 2.2%, indicating potential risks.
